FDA Grants Accelerated Approval to Zanidatamab-hrii for Patients with Previously Treated Unresectable or Metastatic HER2-positive Biliary Tract Cancer By Ogkologos - December 17, 2024 62 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the HERIZON-BTC-01 study Source RELATED ARTICLESMORE FROM AUTHOR Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients with HER2-altered Tumours, Including NSCLC EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab to Unresectable or Advanced HCC ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March MOST POPULAR EMA Recommends Extending Indications for Pembrolizumab to Patients with Advanced Biliary... December 1, 2023 Coping with Grief: An Interview with Author Rebecca Munn September 28, 2020 Waiting for Insurance to Cover Her Mammogram Could Have Cost This... April 9, 2019 Adding Pembrolizumab to Chemotherapy Results in Improved PFS and OS in... November 25, 2024 Load more HOT NEWS Trastuzumab Deruxtecan Shows Durable Anticancer Activity in Patients with Previously Treated... UK Clinical Trial Compares E-cigarettes, Nicotine-Replacement Products for Smoking Cessation Lion With Skin Cancer Has Received Radiation Therapy In Hospital 2021 ASCO Annual Meeting Research Round Up: New Research in Gynecologic...
